Luke Fletcher, MD
Hematology & Oncology · Eugene, ORNPI 1770979098
Payments from drug & device makers
Across 111 payments — averaging $18,402 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.4M
- E.r. Squibb & Sons, L.L.C.$488K
- Pharmaessentia USA Corporation$56K
- Sumitomo Pharma America, Inc.$53K
- Servier Bioinnovation$10K
- CTI Biopharma Corp.$6K
- plus $28K from 19 others
Across 3 payments — averaging $749.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $1,401,339 |
| E.r. Squibb & Sons, L.L.C. | 8 | $487,557 |
| Pharmaessentia USA Corporation | 16 | $55,813 |
| Sumitomo Pharma America, Inc. | 11 | $53,100 |
| Servier Bioinnovation | 2 | $10,400 |
| CTI Biopharma Corp. | 3 | $6,091 |
| Servier Pharmaceuticals LLC | 6 | $5,320 |
| Genentech, Inc. | 5 | $5,086 |
| AbbVie | 7 | $3,531 |
| Astellas Pharma US Inc | 4 | $2,355 |
| Bristol Myers Squibb | 5 | $2,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,100 |
| AstraZeneca | 2 | $1,806 |
| Morphosys, US Inc. | 2 | $1,713 |
| Janssen Scientific Affairs, LLC | 10 | $1,678 |
| Sanofi | 3 | $1,513 |
| Taiho Oncology, Inc. | 3 | $355 |
| Stemline Therapeutics Inc. | 1 | $145 |
| Blueprint Medicines Corporation | 1 | $101 |
| Eli Lilly | 1 | $100 |
| Sobi, Inc | 1 | $76 |
| Amgen | 1 | $65 |
| Pfizer | 1 | $50 |
| Genentech USA, Inc. | 1 | $46 |
| Foundation Medicine, Inc. | 1 | $26 |
How this compares
$2,042,617 in reported general payments places this provider in the 85th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Eugene
- Christopher YasenchakEugene$2.4M
- Miho DoughertyEugene$819K
- James ButrynskiEugene$732K
- Matthew LonerganEugene$202K
- Jae LeeEugene$10K
- Michael HeinrichPortland$25M
- Jay AndersenPortland$8.3M
- Elie TraerPortland$6.5M
- Ian SchnadigTualatin$6.4M
- Jacqueline VukyPortland$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.